Contemporary use of diseasemodifying drugs in the management of patients with early rheumatoid arthritis in Norway

Scandinavian Journal of Rheumatology

Volumn 38, Issue 4, 2009, Pages 240-245

  Nikolaisen, C ^a,b   Kvien, T K ^c,d   Mikkelsen, K ^e   Kaufmann, C ^f   Rodevand E ^g   Nossent, J C ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Rheumatism Hospital   (Norway)

^f Buskerud Central Hospital   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NORWAY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; AGE; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EARLY DIAGNOSIS; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN ASSESSMENT; PROBABILITY; RISK; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORWAY; ODDS RATIO; PAIN MEASUREMENT; PROBABILITY; RISK ASSESSMENT; SEX FACTORS; SULFASALAZINE; TREATMENT OUTCOME;

EID: 70350648683     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802609566     Document Type: Article

References (39)

1. Machold KP, Nell V, Stamm T, Aletaha D, Smolen JS. Early rheumatoid arthritis. Curr Opin Rheumatol 2006;18:282-288
2. Machold KP, Nell VP, Stamm TA, Smolen JS. Aspects of early arthritis. Traditional DMARD therapy: Is it sufficient? Arthritis Res Ther 2006;8:211.
3. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD p for rheumatoid arthritis. Rheumatology (Oxford) 2004;43:206-210
4. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005;44:1394-1398
5. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-2524
6. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: Results from two matched questionnaires within three years. Ann Rheum Dis 2002;61:630-634
7. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: Comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-1374
8. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-318
9. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. AnnRheum Dis 1999;58:220-225
10. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthrit is: A randomisedtrial.FIN-RACotrialgroup. Lancet1999;353:1568-1573
11. Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van't Hof MA, et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:453-458 (Pubitemid 32417416)
12. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712
13. Kirwan JR, Hallgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004;63:688-695
14. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al.ANorwegianDMARDregister: Prescriptions ofDMARDsand biological agents to patientswith inflammatory rheumatic diseases. Clin ExpRheumatol 2005;23:S188-S194.
15. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-912
16. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: A multiparameter prospective study. Arthritis Rheum 2001;44:1736-1743
17. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL.Occurrenceof extraarticulardiseasemanifestations is associated with excessmortality ina communitybased cohort of patientswith rheumatoid arthritis. JRheumatol 2002;29:62-67
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
19. Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008;47:1543-1547
20. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: A global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008;18:228-239
21. Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with presentday standard care in early rheumatoid arthritis.Musculoskeletal Care. Epub ahead of print, DOI 10.1002/msc.136.
22. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: A long-term observational study. J Rheumatol 2002;29:261-266
23. Riise T, Jacobsen BK, Gran JT. Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. Scand J Rheumatol 2001;30:199-202.
24. Ludig A, Guillemin F, Chary-Valckenaere I, Suurmeijer TP, Moum T, Van den Heuvel WJ. Drug consumption in the first years of rheumatoid arthritis in France, the Netherlands, and Norway. A longitudinal study in the early nineties. Scand J Rheumatol 2000;29:352-357
25. Weinblatt ME,Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822
26. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-730
27. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. J Rheumatol 1998;25:238-242
28. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
29. Van der Heijde DM, Van Riel PL, Van Leeuwen MA, Van 't Hof MA, Van Rijswijk MH, Van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-525
30. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000;39(Suppl 1):24-29
31. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-927
32. Graudal N, Tarp U, Jurik AG, Galloe AM, Garred P, Milman N, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. J Rheumatol 2000;27:47-57.
33. Shmerling RH, Delbanco TL. The rheumatoid factor: An analysis of clinical utility. Am J Med 1991;91:528-534
34. Elliott JR, O'Dell J. Rheumatoid arthritis. In West SG, editor. Rheumatology secrets, 2nd edn. Philadelphia: Hanley & Belfus, 2002: 123.
35. Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis: Development over 5 years. J Rheumatol 1995;22:1037-1042
36. Van der Heide A, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-1474
37. Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW.Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann InternMed 2002;136:1-12.
38. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:677-680
39. Nikolaisen C, Rekvig OP, Nossent HC. Diagnostic impact of contemporary biomarker assay for rheumatoid arthritis. Scand J Rheumatol 2007;36:97-100.